1.Primary adrenal NK/T cell lymphoma: a clinicopathologic analysis of six cases.
Sheng Li ZHOU ; Jian Guo WEI ; Bo LI ; Xi Juan WANG ; Zhi Quan GONG ; Pan Hong FAN ; Li Fu WANG ; Rui Jiao ZHAO ; Lei ZHANG ; Ling Fei KONG
Chinese Journal of Pathology 2023;52(7):710-714
		                        		
		                        			
		                        			Objective: To investigate the clinicopathologic features of primary adrenal NK/T cell lymphoma (PANKL). Methods: Six cases of PANKL were collected at Henan Provincial People's Hospital from January 2000 to December 2021. The clinicopathologic features including morphology, immunophenotype, treatment and prognosis were retrospectively analyzed, and relevant literature was reviewed. Results: There were two males and four females. The median age was 63 years (ranged from 57 to 68 years). The tumors involved bilateral adrenal glands in 4 cases and unilateral adrenal gland in 2 cases. The main clinical symptom was low back pain without obvious cause. Serum lactate dehydrogenase (LDH) is elevated in five cases. The imaging feature was rapidly enlarging mass initially confined to unilateral/bilateral adrenal glands. Morphologically, the lymphoid cells were mainly medium-sized with a diffuse growth pattern. Coagulative necrosis and nuclear fragmentation were common. Angioinvasion was seen. Immunophenotypically, the neoplastic cells were positive for CD3, CD56 and TIA-1 while CD5 was negative in 5 cases. All cases were positive for EBER by in situ hybridization with more than 80% proliferative activity by Ki-67. Four cases received chemotherapy, one case underwent surgery, and one case underwent surgery with chemotherapy. Follow-up was done in 5 cases; one case was lost to follow-up. Three patients died with a median survival of 11.6 months (3-42 months). Conclusions: PANKL is rare with highly aggressive clinical presentation and poor prognosis. Accurate diagnosis entails correlation of histomorphology, immunohistochemistry, EBER in situ hybridization and clinical history.
		                        		
		                        		
		                        		
		                        			Male
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Lymphoma, T-Cell, Peripheral/pathology*
		                        			;
		                        		
		                        			Killer Cells, Natural/pathology*
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Immunophenotyping
		                        			
		                        		
		                        	
2.Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma.
Yun Fei SHI ; Hao Jie WANG ; Wei Ping LIU ; Lan MI ; Meng Ping LONG ; Yan Fei LIU ; Yu Mei LAI ; Li Xin ZHOU ; Xin Ting DIAO ; Xiang Hong LI
Journal of Peking University(Health Sciences) 2023;55(3):521-529
		                        		
		                        			OBJECTIVE:
		                        			To analyze the clinicopathological features, molecular changes and prognostic factors in angioimmunoblastic T-cell lymphoma (AITL).
		                        		
		                        			METHODS:
		                        			Sixty-one cases AITL diagnosed by Department of Pathology of Peking University Cancer Hospital were collected with their clinical data. Morphologically, they were classified as typeⅠ[lymphoid tissue reactive hyperplasia (LRH) like]; typeⅡ[marginal zone lymphoma(MZL)like] and type Ⅲ [peripheral T-cell lymphoma, not specified (PTCL-NOS) like]. Immunohistochemical staining was used to evaluate the presence of follicular helper T-cell (TFH) phenotype, proliferation of extra germinal center (GC) follicular dendritic cells (FDCs), presence of Hodgkin and Reed-Sternberg (HRS)-like cells and large B transformation. The density of Epstein-Barr virus (EBV) + cells was counted with slides stained by Epstein-Barr virus encoded RNA (EBER) in situ hybridization on high power field (HPF). T-cell receptor / immunoglobulin gene (TCR/IG) clonality and targeted exome sequencing (TES) test were performed when necessary. SPSS 22.0 software was used for statistical analysis.
		                        		
		                        			RESULTS:
		                        			Morphological subtype (%): 11.4% (7/61) cases were classified as type Ⅰ; 50.8% (31/61) as type Ⅱ; 37.8% (23/61) as type Ⅲ. 83.6% (51/61) cases showed classical TFH immunophenotype. With variable extra-GC FDC meshwork proliferation (median 20.0%); 23.0% (14/61) had HRS-like cells; 11.5% (7/61) with large B transformation. 42.6% (26/61) of cases with high counts of EBV. 57.9% (11/19) TCR+/IG-, 26.3% (5/19) TCR+/IG+, 10.5% (2/19) were TCR-/IG-, and 5.3% (1/19) TCR-/IG+. Mutation frequencies by TES were 66.7% (20/30) for RHOA, 23.3% (7/30) for IDH2 mutation, 80.0% (24/30) for TET2 mutation, and 33.3% (10/30) DNMT3A mutation. Integrated analysis divided into four groups: (1) IDH2 and RHOA co-mutation group (7 cases): 6 cases were type Ⅱ, 1 case was type Ⅲ; all with typical TFH phenotype; HRS-like cells and large B transformation were not found; (2) RHOA single mutation group (13 cases): 1 case was type Ⅰ, 6 cases were type Ⅱ, 6 cases were type Ⅲ; 5 cases without typical TFH phenotype; 6 cases had HRS-like cells, and 2 cases with large B transformation. Atypically, 1 case showed TCR-/IG-, 1 case with TCR-/IG+, and 1 case with TCR+/IG+; (3) TET2 and/or DNMT3A mutation alone group (7 cases): 3 cases were type Ⅱ, 4 cases were type Ⅲ, all cases were found with typical TFH phenotype; 2 cases had HRS-like cells, 2 cases with large B transformation, and atypically; (4) non-mutation group (3 cases), all were type Ⅱ, with typical TFH phenotype, with significant extra-GC FDC proliferation, without HRS-like cells and large B transformation. Atypically, 1 case was TCR-/IG-. Univariate analysis confirmed that higher density of EBV positive cell was independent adverse prognostic factors for both overall survival (OS) and progression free survival(PFS), (P=0.017 and P=0.046).
		                        		
		                        			CONCLUSION
		                        			Pathological diagnoses of ALTL cases with HRS-like cells, large B transformation or type Ⅰ are difficult. Although TCR/IG gene rearrangement test is helpful but still with limitation. TES involving RHOA, IDH2, TET2, DNMT3A can robustly assist in the differential diagnosis of those difficult cases. Higher density of EBV positive cells counts in tumor tissue might be an indicator for poor survival.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Epstein-Barr Virus Infections/genetics*
		                        			;
		                        		
		                        			Herpesvirus 4, Human/genetics*
		                        			;
		                        		
		                        			T-Lymphocytes, Helper-Inducer/pathology*
		                        			;
		                        		
		                        			Immunoblastic Lymphadenopathy/pathology*
		                        			;
		                        		
		                        			Lymphoma, T-Cell, Peripheral/pathology*
		                        			;
		                        		
		                        			Receptors, Antigen, T-Cell
		                        			
		                        		
		                        	
3.Primary central nervous system T-cell lymphoma in children and adolescents: a clinicopathological analysis of five cases.
Pei Zhu HU ; Heng Yan ZHANG ; Guan Nan WANG ; Wu Gan ZHAO ; Dan Dan ZHANG ; Wen Cai LI
Chinese Journal of Pathology 2023;52(1):37-42
		                        		
		                        			
		                        			Objective: To study the clinicopathological characteristics, and further understand primary central nervous system T-cell lymphoma (PCNSTCL) in children and adolescents. Methods: Five cases of PCNSTCL in children and adolescents were collected from December 2016 to December 2021 at the First Affiliated Hospital of Zhengzhou University. The clinicopathological characteristics, immunophenotypic, and molecular pathologic features were analyzed, and relevant literatures reviewed. Results: There were two male and three female patients with a median age of 14 years (range 11 to 18 years). There were two peripheral T-cell lymphomas, not otherwise specified, two anaplastic large cell lymphoma, ALK-positive and one NK/T cell lymphoma. Pathologically, the tumor cells showed a variable histomorphologic spectrum, including small, medium and large cells with diffuse growth pattern and perivascular accentuation. Immunohistochemistry and in situ hybridization showed CD3 expression in four cases, and CD3 was lost in one case. CD5 expression was lost in four cases and retained in one case. ALK and CD30 were expressed in two cases. One tumor expressed CD56 and Epstein-Barr virus-encoded RNA. All cases showed a cytotoxic phenotype with expression of TIA1 and granzyme B. Three cases had a high Ki-67 index (>50%). T-cell receptor (TCR) gene rearrangement was clonal in two cases. Conclusions: PCNSTCL is rare, especially in children and adolescents. The morphology of PCNSTCL is diverse. Immunohistochemistry and TCR gene rearrangement play important roles in the diagnosis.
		                        		
		                        		
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Central Nervous System/pathology*
		                        			;
		                        		
		                        			Central Nervous System Neoplasms/pathology*
		                        			;
		                        		
		                        			Epstein-Barr Virus Infections
		                        			;
		                        		
		                        			Herpesvirus 4, Human
		                        			;
		                        		
		                        			Lymphoma, T-Cell/pathology*
		                        			;
		                        		
		                        			Lymphoma, T-Cell, Peripheral/genetics*
		                        			;
		                        		
		                        			Receptor Protein-Tyrosine Kinases/genetics*
		                        			;
		                        		
		                        			Receptors, Antigen, T-Cell
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Adolescent
		                        			
		                        		
		                        	
5.Progressively transformed germinal center-like follicular T-cell lymphoma:a clinicopathological analysis of 14 cases.
Y Y ZHENG ; J L XIE ; Y L ZHANG ; X G ZHOU
Chinese Journal of Pathology 2023;52(11):1144-1150
		                        		
		                        			
		                        			Objective: To investigate the clinicopathologic features of progressively transformed germinal center-like follicular T-cell lymphoma (PTGC-like FTCL). Methods: The clinicopathologic data of 14 PTGC-like FTCL cases that were diagnosed at the Beijing Friendship Hospital Affiliated to the Capital Medical University from January 2017 to January 2022 were retrospectively collected. Clinicopathological features, immunophenotype, and Epstein-Barr virus (EBV) infection status were analyzed in these cases. Polymerase chain reaction (PCR) was performed to detect the clonal gene rearrangements of T cell receptor (TCR) and the immunoglobulin (Ig) in 10 and 8 cases, respectively. Results: The male to female ratio was 5∶2. The median age was 61 years (range 32-70 years). All patients had lymphadenopathy at the time of diagnosis. By using the Ann Arbor system staging, seven cases were classified as stage Ⅰ-Ⅱ, and seven cases as stage Ⅲ-Ⅳ. Seven cases had B symptoms, four cases had splenomegaly, and two cases had skin rash and pruritus. Previously, three cases were diagnosed as classic Hodgkin's lymphoma, three cases as small B-cell lymphoma, two cases as atypical lymphoid hyperplasia unable to exclude angioimmunoblastic T-cell lymphoma (AITL), one case as EBV-associated lymphoproliferative disorder, and one case as peripheral T-cell lymphoma (PTCL) associated with the proliferation of B cells. All the 14 cases showed that the large nodules were composed of mature CD20+, IgD+B lymphocytes admixed with small aggregates of neoplastic cells with pale to clear cytoplasm. Moreover, hyperplastic germinal centers (GCs) and Hodgkin/Reed-Sternberg-like (HRS-like) cells were seen within these nodules in two and five cases, respectively. The neoplastic cells expressed CD3 (14/14), CD4 (14/14), PD1 (14/14), ICOS (14/14), CD10 (9/14), bcl-6 (12/14), CXCL13 (10/14), and CD30 (10/14). The HRS-like cells in five cases expressed CD20 (2/5), PAX5 (5/5), CD30 (5/5), CD15 (2/5), LCA (0/5), OCT2 (5/5) and BOB1 (2/5). Moreover, neoplastic T cells formed rosettes around HRS-like cells. EBV-encoded RNA (EBER) in situ hybridization showed scattered, small, positive bystander B lymphocytes in 8/14 cases, including 3/5 cases containing HRS-like cells. All tested cases (including five with HRS-like cells) showed monoclonal TCR gene rearrangement and polyclonal Ig gene rearrangement. Conclusions: PTGC-like FTCL is a rare tumor originated from T-follicular helper cells. It could be distinguished from angioimmunoblastic T-cell lymphoma by the formation of follicular structure, and lack of follicular dendritic cell proliferation outside the follicles and the polymorphous inflammatory background. In addition, it should be differentiated from lymphocyte-rich classical Hodgkin's lymphoma and low-grade B cell lymphoma.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Lymphoma, T-Cell, Peripheral/pathology*
		                        			;
		                        		
		                        			Reed-Sternberg Cells/pathology*
		                        			;
		                        		
		                        			Epstein-Barr Virus Infections
		                        			;
		                        		
		                        			Hyperplasia/pathology*
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Herpesvirus 4, Human/genetics*
		                        			;
		                        		
		                        			Immunoblastic Lymphadenopathy/pathology*
		                        			;
		                        		
		                        			Hodgkin Disease/pathology*
		                        			;
		                        		
		                        			Germinal Center/pathology*
		                        			;
		                        		
		                        			Receptors, Antigen, T-Cell
		                        			
		                        		
		                        	
9.Clinicopathological features of mature T/NK cell lymphoma with aberrant CD20 or CD79α expression.
Du Juan LI ; Hong KANG ; Lei ZHANG ; Zi Guang XU ; Xiao Yan WANG ; Li Fu WANG ; Xiao Xia SONG ; Ling Fei KONG
Chinese Journal of Pathology 2022;51(5):413-418
		                        		
		                        			
		                        			Objective: To investigate the clinicopathological characteristics and prognosis of mature T/NK cell lymphomas with aberrant CD20 or CD79α expression. Methods: A retrospective analysis of 641 cases of mature T/NK cell lymphoma diagnosed from January 2014 to December 2020 was performed, and 14 cases of CD20-positive and one case of CD79α-positive mature T/NK-cell lymphoma were identified. Histological examination, immunohistochemical characterization, in situ hybridization for Epstein-Barr virus encoded early RNA (EBER), and PCR testing for immunoglobulin and T cell receptor (TCR) gene rearrangements were performed. Clinicopathological characteristics of these lymphomas were analyzed. Results: There were 13 males and 2 females, with a median age of 56 years. There were 8 cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), 3 cases of extranodal NK/T-cell lymphoma, nasal type (ENKTCL), 2 cases of monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) and 2 cases of angioimmunoblastic T-cell lymphoma (AITL). Twelve cases were stage Ⅲ or Ⅳ lymphomas. The prognosis was overall poor. The histology, immunophenotype and TCR gene rearrangement were not significantly different from the corresponding types of lymphoma. Ki-67 proliferation index was over 70% in all cases. The expression of CD20 or CD79α was weak and heterogeneous. All 15 case of Ig gene rearrangement were polyclonal. Conclusions: Mature T/NK cell lymphoma with abnormal expression of CD20 or CD79α is rare, commonly found in advanced stage, and associated with poor prognosis. The expression of CD20 or CD79α in these cases is weaker than the corresponding mature T/NK cell lymphomas, while its proliferation index is higher. Histomorphology, extensive immunoprofiling and molecular detection are required for accurate diagnosis.
		                        		
		                        		
		                        		
		                        			Antigens, CD20
		                        			;
		                        		
		                        			Epstein-Barr Virus Infections/complications*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Herpesvirus 4, Human/genetics*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Killer Cells, Natural/pathology*
		                        			;
		                        		
		                        			Lymphoma, T-Cell, Peripheral/pathology*
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Receptors, Antigen, T-Cell
		                        			;
		                        		
		                        			Retrospective Studies
		                        			
		                        		
		                        	
10.Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
Seung Shin LEE ; Sung Hoon JUNG ; Jae Sook AHN ; Yeo Kyeoung KIM ; Min Seok CHO ; Seung Yeon JUNG ; Je Jung LEE ; Hyeoung Joon KIM ; Deok Hwan YANG
Journal of Korean Medical Science 2016;31(7):1160-1163
		                        		
		                        			
		                        			Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities, and poor functional status. Thus, treatment of elderly patients with relapsed or refractory PTCL remains a challenge for clinicians. A recent study disclosed that pralatrexate has a synergistic effect in combination with bortezomib. Weekly pralatrexate and bortezomib were administered intravenously for 3 weeks in a 4-week cycle. Of 5 patients, one achieved complete response after 4 cycles which has lasted 12 months until now. Another patient attained partial response after 2 cycles. Only 1 patient experienced grade 3 thrombocytopenia and neutropenia. Two patients suffered from grade 3 mucositis. Combination therapy with pralatrexate and bortezomib may be used as a salvage therapy for relapsed or refractory PTCL in the elderly with a favorable safety profile.
		                        		
		                        		
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aminopterin/adverse effects/*analogs & derivatives/therapeutic use
		                        			;
		                        		
		                        			Antineoplastic Agents/adverse effects/*therapeutic use
		                        			;
		                        		
		                        			Bortezomib/adverse effects/*therapeutic use
		                        			;
		                        		
		                        			Drug Administration Schedule
		                        			;
		                        		
		                        			Drug Therapy, Combination
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lymphoma, T-Cell, Peripheral/diagnostic imaging/*drug therapy/pathology
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Neoplasm Recurrence, Local
		                        			;
		                        		
		                        			Neutropenia/etiology
		                        			;
		                        		
		                        			Positron Emission Tomography Computed Tomography
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail